• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Carsgen Therapeutics Holdings Ltd.

Headquarters: Shanghai, China
Website: http://www.carsgen.com
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Zong Hai Li, MD, PhD
Number Of Employees: 516
Enterprise Value: $214,078,510
PE Ratio: -10.8
Exchange/Ticker 1: HKEX:2171
Exchange/Ticker 2: N/A
Latest Market Cap: $1,056,899,630

BioCentury | Jan 4, 2025
Management Tracks

Four companies announce new CFOs

Plus: Jia joins Grit Bio and Riley joins Avalo
Read More
BioCentury | May 24, 2024
Product Development

Clinical Report: Merus data stand out among ASCO highlights

Clinical data released ahead of ASCO from Merus, Caribou, BioNTech and more
Read More
BioCentury | Apr 2, 2024
Data Byte

With Astellas’ Vyloy, GI tumor target CLDN18.2 gets first approval

At least 32 other programs targeting CLDN18.2, spanning six modalities, are in clinical testing for gastrointestinal tumors
Read More
BioCentury | Dec 14, 2023
Deals

Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal

Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
Read More
BioCentury | Oct 21, 2023
Management Tracks

Daly to succeed McEnany as Catalyst CEO 

Plus: Hennemand joins Covant as CEO and updates from Invitae, Immunome, Antiva, Omeros, Actimed and RegCell 
Read More
BioCentury | Sep 11, 2023
Deals

Sept. 11 Quick Takes: Surprise miss for Acelyrin in hidradenitis suppurativa

Plus: Moderna, Immatics in oncology discovery, development deal, and updates from Takeda, Novartis, Crinetics, Verona, Nestlé
Read More
BioCentury | Sep 9, 2023
Deals

CAR T collaborations: the next cross-border deal trend?

BioCentury analyzes the opportunity for East-West collaborations to drive CAR T cell development
Read More
BioCentury | Aug 22, 2023
Regulation

Aug. 21 Quick Takes: Pfizer’s Abrysvo granted maternal indication

Plus: Andreessen Horowitz co-leads $200M round for AI company Genesis, Leqembi closes in on Japan approval and more
Read More
BioCentury | Feb 28, 2023
Data Byte

AZ enters crowded CLDN18.2 clinical race via Keymed deal

At least 28 therapies targeting CLDN18.2 have started clinical trials for cancer
Read More
BioCentury | Jan 18, 2023
Regulation

Jan. 17 Quick Takes: Moderna now in RSV vaccine regulatory race

Plus: Leap, Flame propose merger and updates from Elicio, Angion, Huadong, CARsgen and more 
Read More
Items per page:
1 - 10 of 18